Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (PVLA), has been a consistent seller of company stock over the past year, with Form 4 filings showing 44 total transactions—all sell-side—amounting to roughly $4.2 million in open-market sales. The pattern is unambiguous: zero purchases, zero acquisitions, and a steady cadence of monthly disposals since at least March 2026. Her most recent activity on July 15, 2026, included four separate sales totaling approximately $642,000, with individual transactions ranging from $76,805 to $287,133. That same day, she also exercised options valued at $34,883, though those exercises appear mechanical in nature, immediately preceding the sales.
The selling has been methodical rather than reactive. In June 2026, Goin sold approximately $476,000 worth of PVLA shares across three transactions, while May brought roughly $476,000 in sales alongside option exercises. April saw her most active month, with five sales totaling about $547,000. The March 18, 2026 filing shows two sales worth approximately $241,000. Each monthly cluster follows the same structure: option exercises paired with open-market sales, suggesting a planned liquidation strategy tied to equity compensation rather than opportunistic timing.
Notably, Goin has not made a single open-market purchase of PVLA stock during this period, and her total buy value stands at zero. The absence of any "P" transactions—the only code indicating conviction buying—combined with the regular, sizable sales paints a clear directional picture. While the option exercises are standard compensation mechanics, the consistent conversion of those shares into cash, month after month, represents a sustained reduction in her direct ownership stake in the company.
AI-assisted summary